Frank Rimerman Advisors’s Royalty Pharma RPRX Stock Holding History

Frank Rimerman Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$588K	Hold	10,493	–	–	0.03%	372
2026 Q1	$503K	Hold	10,493	–	–	0.03%	375
2025 Q4	$405K	Sell	10,493 -19	-0.2%	-$725	0.03%	431
2025 Q3	$371K	Buy	10,512 +57	+0.5%	+$2.06K	0.02%	430
2025 Q2	$377K	Buy	10,455 +3,863	+59%	+$128K	0.03%	399
2025 Q1	$205K	Buy	+6,592	New	+$209K	0.02%	496

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frank Rimerman Advisors's RPRX Position: Q2 2026 in Review

Frank Rimerman Advisors held its Royalty Pharma (RPRX) position steady in Q2 2026 at 10,493 shares worth $588K. The position accounts for 0.03% of the portfolio, ranked #372.

Frank Rimerman Advisors first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Frank Rimerman Advisors held 10,493 shares of Royalty Pharma worth $588K as of Q2 2026.
Frank Rimerman Advisors left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up 0.03% of Frank Rimerman Advisors's portfolio in Q2 2026, its #372 holding.
Frank Rimerman Advisors first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.